These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 24100872)

  • 41. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
    Ségéral O; Limsreng S; Nouhin J; Hak C; Ngin S; De Lavaissière M; Goujard C; Taburet AM; Nerrienet E; Delfraissy JF; Ouk V; Dulioust A
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):597-603. PubMed ID: 21083413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting.
    Maiga AI; Fofana DB; Cisse M; Diallo F; Maiga MY; Traore HA; Maiga IA; Sylla A; Fofana D; Taiwo B; Murphy R; Katlama C; Tounkara A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Dec; 67(12):2943-8. PubMed ID: 22888273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic.
    Klibanov OM; Dolder CR; Assefa F; Ekwonu TJ
    AIDS Patient Care STDS; 2013 Apr; 27(4):205-7. PubMed ID: 23514132
    [No Abstract]   [Full Text] [Related]  

  • 46. Advances in antiretroviral therapy.
    Taylor B; Olender S; Wilkin TJ; Hammer SM
    Top Antivir Med; 2011; 19(2):69-97. PubMed ID: 21868824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laboratory monitoring for antiretroviral therapy in low-resource settings.
    Boyer S; Laurent C; Kouanfack C; Delaporte E; Moatti JP
    Lancet Infect Dis; 2013 Sep; 13(9):739. PubMed ID: 23969214
    [No Abstract]   [Full Text] [Related]  

  • 48. HIV resistance testing. A clinical tool.
    Paul SM; Jorden VS
    N J Med; 2003 Sep; 100(9 Suppl):44-9; quiz 75-6. PubMed ID: 14556603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving first-line antiretroviral therapy in resource-limited settings.
    Ford N; Calmy A
    Curr Opin HIV AIDS; 2010 Jan; 5(1):38-47. PubMed ID: 20046146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
    Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
    Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.
    Janssens B; Raleigh B; Soeung S; Akao K; Te V; Gupta J; Vun MC; Ford N; Nouhin J; Nerrienet E
    Pediatrics; 2007 Nov; 120(5):e1134-40. PubMed ID: 17954553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral therapy in treatment-naïve patients with HIV infection.
    Camacho R; Teófilo E
    Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S3-11. PubMed ID: 22156777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic drug monitoring of antiretroviral therapy.
    Rakhmanina NY; van den Anker JN; Soldin SJ
    AIDS Patient Care STDS; 2004 Jan; 18(1):7-14. PubMed ID: 15006189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings.
    Bertagnolio S; Perno CF; Vella S; Pillay D
    J Infect Dis; 2013 Jun; 207 Suppl 2():S45-8. PubMed ID: 23687288
    [No Abstract]   [Full Text] [Related]  

  • 55. Monitoring of antiretroviral therapy in low-resource settings.
    Lawn SD; Bekker LG; Calmy A; Wood R
    Lancet; 2008 Jul; 372(9635):287-8; author reply 289. PubMed ID: 18657697
    [No Abstract]   [Full Text] [Related]  

  • 56. Antiretroviral Therapy.
    Brock JB; Henderson H
    J Miss State Med Assoc; 2015 Jun; 56(6):166, 171-2. PubMed ID: 26242056
    [No Abstract]   [Full Text] [Related]  

  • 57. ART for children: what to start and when to switch.
    Sutcliffe CG; Moss WJ
    Lancet Infect Dis; 2011 Apr; 11(4):254-5. PubMed ID: 21288775
    [No Abstract]   [Full Text] [Related]  

  • 58. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
    Kumarasamy N; Madhavan V; Venkatesh KK; Saravanan S; Kantor R; Balakrishnan P; Devaleenal B; Poongulali S; Yepthomi T; Solomon S; Mayer KH; Benson C; Schooley R
    Clin Infect Dis; 2009 Jul; 49(2):306-9. PubMed ID: 19522657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Salvage therapy for HIV infection: when and how.
    Núñez M; Soriano V
    AIDS Patient Care STDS; 2000 Sep; 14(9):465-76. PubMed ID: 11051629
    [No Abstract]   [Full Text] [Related]  

  • 60. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.
    Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers R; Alvarez-Uria G; Streinu-Cercel A; Ene L; Wensing A; Reiss P; van Sighem AI; Nelson M; Emery S; Montaner JS; Lane HC; Larder BA;
    J Antimicrob Chemother; 2014 Apr; 69(4):1104-10. PubMed ID: 24275116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.